Cytogen (US) signs OncoScint partners:
This article was originally published in Clinica
Cytogen (US) has signed letters of intent with CIS bio international (France) and Faulding (Canada) to market the OncoScint CR/OV imaging agent for detecting colorectal and ovarian cancers. CIS bio will distribute OncoScint in Europe and countries excluding North America, while Faulding is to distribute the agent in Canada. OncoScint is already marketed in the US by Cytogen's nuclear oncology department and has marketing approval in 13 European countries. It was previously marketed in Europe by EuroCetus, which was acquired by Chiron.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.